Orchid Pharma Limited — Others, 12-02-2025: Monitoring Agency Report

Orchid Pharma has shared its Monitoring Agency Report for Quarter-III of FY 2024-25, revealing no deviations in the utilization of proceeds from its recent Qualified Institutions Placement, totaling ₹400 crore. The report highlights the allocated funds, with ₹190.24 crore utilized so far, primarily for repayment of borrowings and initial expenditures in the Jammu manufacturing facility and Alathur capital projects. Delays have been noted in implementation timelines, largely attributed to land acquisition issues for the Jammu facility. Investors may view this report positively due to the reassured management of funds, although the delays introduce potential risks to the execution timeline.